Similarly, in an immunocompetent model of intraperitoneal ovarian cancer (ID8 p53-/-), combination treatment with Lipofermata provided the best survival advantage, while neither treatment alone provided a survival benefit (Figure 4G). Here, TP53 is linked to ovarian cancer.